How the Rest of the World’s Capacity-Building Impacts the Global Regulatory Dossier
This article was originally published in The Gold Sheet
Emerging nations are supplanting the developed world’s vision of global pharmaceutical regulatory harmonization with one of their own: capacity-building and convergence. A main point of focus will be creating the regulatory review and manufacturing capability needed to launch biosimilars in countries like Brazil and Taiwan.
You may also be interested in...
A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.
Executive order calls for short-term and long-term study, broad consultation, coordination with allies.
Agency outlines plans to authorize variant COVID-19 vaccines and therapeutics based on swift quality assessments.